Skip to content

Study · Randomized controlled trial · 2013

10 results

Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women.

Shiraki M, Sugimoto T, Nakamura T

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA24 Oct 2012Cited by 34 (Europe PMC)

PMID23093347 (opens in a new tab)PMCIDPMC3536955 (opens in a new tab)DOI10.1007/s00198-012-2159-7 (opens in a new tab)PepBankPUB-23093347
Read at sourcePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In postmenopausal women, teriparatide plasma concentration increased with dose.

    In plain wordsIn postmenopausal women, the higher teriparatide dose produced higher blood concentrations than the lower dose.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseDose-dependent plasma concentration
    Study

    n: not reported in source

    Comparator
    Lower teriparatide dose
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    28.2 or 56.5 μg single injection · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Teriparatide plasma concentration increased in a dose-dependent manner, and the maximum concentration was achieved 1 h after injection.
    1 context sentence
    Summary · context
    Pharmacokinetics and calcium metabolism and bone turnover parameters were measured in 30 postmenopausal women after two doses of teriparatide (28.2 or 56.5 μg injection) or placebo in a randomized, double-blind, placebo-controlled study.
  2. 02HumanRandomized controlled trialPharmacokinetics

    In postmenopausal women, teriparatide reached maximum plasma concentration one hour after injection.

    In plain wordsIn postmenopausal women, teriparatide blood concentrations peaked one hour after injection.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableTime to maximum concentration
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    28.2 or 56.5 μg single injection · subcutaneousAs given in this study (human).

    Measurements

    Time to maximum concentration
    1 h
    after injection

    Source sentences

    Summary
    Teriparatide plasma concentration increased in a dose-dependent manner, and the maximum concentration was achieved 1 h after injection.
    1 context sentence
    Summary · context
    Pharmacokinetics and calcium metabolism and bone turnover parameters were measured in 30 postmenopausal women after two doses of teriparatide (28.2 or 56.5 μg injection) or placebo in a randomized, double-blind, placebo-controlled study.
  3. 03HumanRandomized controlled trialActivity measurement

    In postmenopausal women, serum calcium transiently increased after teriparatide injection.

    In plain wordsIn postmenopausal women, blood calcium temporarily increased after teriparatide injection compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum calcium
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    28.2 or 56.5 μg single injection · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Serum levels of calcium and phosphorus were transiently increased and decreased after teriparatide injection, respectively.
    1 context sentence
    Summary · context
    Pharmacokinetics and calcium metabolism and bone turnover parameters were measured in 30 postmenopausal women after two doses of teriparatide (28.2 or 56.5 μg injection) or placebo in a randomized, double-blind, placebo-controlled study.
  4. 04HumanRandomized controlled trialActivity measurement

    In postmenopausal women, serum phosphorus transiently decreased after teriparatide injection.

    In plain wordsIn postmenopausal women, blood phosphorus temporarily decreased after teriparatide injection compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseSerum phosphorus
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    28.2 or 56.5 μg single injection · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Serum levels of calcium and phosphorus were transiently increased and decreased after teriparatide injection, respectively.
    1 context sentence
    Summary · context
    Pharmacokinetics and calcium metabolism and bone turnover parameters were measured in 30 postmenopausal women after two doses of teriparatide (28.2 or 56.5 μg injection) or placebo in a randomized, double-blind, placebo-controlled study.
  5. 05HumanRandomized controlled trialActivity measurement

    In postmenopausal women, the lower teriparatide dose increased serum 1,25-dihydroxy vitamin D by approximately 80% from baseline after two days.

    In plain wordsIn postmenopausal women, the lower teriparatide dose increased active vitamin D compared with baseline after two days.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseVitamin D after lower dose
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    28.2 μg single injection · subcutaneousAs given in this study (human).

    Measurements

    1,25-dihydroxy vitamin D increase
    ≈ 80%
    2 days after injection, 28.2 μg dose, from baseline

    Source sentences

    Summary
    Two days after injection, the serum level of 1,25-dihydroxy vitamin D was increased by ~80 % from baseline for both doses of teriparatide.
    1 context sentence
    Summary · context
    Pharmacokinetics and calcium metabolism and bone turnover parameters were measured in 30 postmenopausal women after two doses of teriparatide (28.2 or 56.5 μg injection) or placebo in a randomized, double-blind, placebo-controlled study.
  6. 06HumanRandomized controlled trialActivity measurement

    In postmenopausal women, the higher teriparatide dose increased serum 1,25-dihydroxy vitamin D by approximately 80% from baseline after two days.

    In plain wordsIn postmenopausal women, the higher teriparatide dose increased active vitamin D compared with baseline after two days.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseVitamin D after higher dose
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    56.5 μg single injection · subcutaneousAs given in this study (human).

    Measurements

    1,25-dihydroxy vitamin D increase
    ≈ 80%
    2 days after injection, 56.5 μg dose, from baseline

    Source sentences

    Summary
    Two days after injection, the serum level of 1,25-dihydroxy vitamin D was increased by ~80 % from baseline for both doses of teriparatide.
    1 context sentence
    Summary · context
    Pharmacokinetics and calcium metabolism and bone turnover parameters were measured in 30 postmenopausal women after two doses of teriparatide (28.2 or 56.5 μg injection) or placebo in a randomized, double-blind, placebo-controlled study.
  7. 07HumanRandomized controlled trialActivity measurement

    In postmenopausal women, osteocalcin decreased during the first 24 hours after teriparatide, then increased approximately 10% for 14 days.

    In plain wordsIn postmenopausal women, osteocalcin first decreased after teriparatide, then increased compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    MixedOsteocalcin time course
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    28.2 or 56.5 μg single injection · subcutaneousAs given in this study (human).

    Measurements

    Osteocalcin increase
    ≈ 10%
    over 14 days after initial fall in first 24 h

    Source sentences

    Summary
    Serum levels of osteocalcin and procollagen type I N-terminal propeptide decreased during the first 24 h followed by a ~10 % increase for 14 days.
    1 context sentence
    Summary · context
    Pharmacokinetics and calcium metabolism and bone turnover parameters were measured in 30 postmenopausal women after two doses of teriparatide (28.2 or 56.5 μg injection) or placebo in a randomized, double-blind, placebo-controlled study.
  8. 08HumanRandomized controlled trialActivity measurement

    In postmenopausal women, P1NP decreased during the first 24 hours after teriparatide, then increased approximately 10% for 14 days.

    In plain wordsIn postmenopausal women, P1NP first decreased after teriparatide, then increased compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    MixedP1NP time course
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    28.2 or 56.5 μg single injection · subcutaneousAs given in this study (human).

    Measurements

    P1NP increase
    ≈ 10%
    over 14 days after initial fall in first 24 h

    Source sentences

    Summary
    Serum levels of osteocalcin and procollagen type I N-terminal propeptide decreased during the first 24 h followed by a ~10 % increase for 14 days.
    1 context sentence
    Summary · context
    Pharmacokinetics and calcium metabolism and bone turnover parameters were measured in 30 postmenopausal women after two doses of teriparatide (28.2 or 56.5 μg injection) or placebo in a randomized, double-blind, placebo-controlled study.
  9. 09HumanRandomized controlled trialActivity measurement

    In postmenopausal women, NTX increased during the first 24 hours after teriparatide, then showed dose-dependent suppression for 14 days.

    In plain wordsIn postmenopausal women, NTX first increased after teriparatide, then decreased compared with baseline, with a dose-dependent effect.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    MixedSerum NTX time course
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    28.2 or 56.5 μg single injection · subcutaneousAs given in this study (human).

    Measurements

    NTX suppression
    10 to 12%
    relative to baseline

    Source sentences

    Summary
    The serum level of cross-linked N-telopeptide (NTX) of type I collagen increased during the first 24 h followed by a 10 to 12 % dose-dependent suppression from baseline for 14 days.
    1 context sentence
    Summary · context
    Pharmacokinetics and calcium metabolism and bone turnover parameters were measured in 30 postmenopausal women after two doses of teriparatide (28.2 or 56.5 μg injection) or placebo in a randomized, double-blind, placebo-controlled study.
  10. 10HumanRandomized controlled trialActivity measurement

    In postmenopausal women, urinary CTX changed in the same direction as serum NTX after teriparatide, without dose dependence.

    In plain wordsIn postmenopausal women, urinary CTX first increased after teriparatide, then decreased compared with baseline, without a dose-dependent effect.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    MixedUrinary CTX time course
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    28.2 or 56.5 μg single injection · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Urinary cross-linked C-telopeptide of type I collagen changes occurred in the same direction as serum NTX, but not dose dependently.
    2 context sentences
    Summary · context
    The serum level of cross-linked N-telopeptide (NTX) of type I collagen increased during the first 24 h followed by a 10 to 12 % dose-dependent suppression from baseline for 14 days.
    Summary · context
    Pharmacokinetics and calcium metabolism and bone turnover parameters were measured in 30 postmenopausal women after two doses of teriparatide (28.2 or 56.5 μg injection) or placebo in a randomized, double-blind, placebo-controlled study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.